| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ID: ALA4237740
Max Phase: Preclinical
Molecular Formula: C18H14F9N3O
Molecular Weight: 459.31
Molecule Type: Small molecule
Associated Items:
Representations
Canonical SMILES: C[C@H](NC(=O)N[C@@H](c1ccc(C(F)(F)F)cc1)c1ncccc1C(F)(F)F)C(F)(F)F
Standard InChI: InChI=1S/C18H14F9N3O/c1-9(16(19,20)21)29-15(31)30-13(10-4-6-11(7-5-10)17(22,23)24)14-12(18(25,26)27)3-2-8-28-14/h2-9,13H,1H3,(H2,29,30,31)/t9-,13-/m0/s1
Standard InChI Key: ONZGGZVXEGIWTB-ZANVPECISA-N
Associated Targets(Human)
Transient receptor potential cation channel subfamily M member 8 1168 Activities
Pregnane X receptor 6667 Activities
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Associated Targets(non-human)
Transient receptor potential cation channel subfamily M member 8 202 Activities
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 459.31 | Molecular Weight (Monoisotopic): 459.0993 | AlogP: 5.46 | #Rotatable Bonds: 4 |
| Polar Surface Area: 54.02 | Molecular Species: NEUTRAL | HBA: 2 | HBD: 2 |
| #RO5 Violations: 1 | HBA (Lipinski): 4 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 1 |
| CX Acidic pKa: 10.29 | CX Basic pKa: 2.68 | CX LogP: 4.74 | CX LogD: 4.74 |
| Aromatic Rings: 2 | Heavy Atoms: 31 | QED Weighted: 0.60 | Np Likeness Score: -1.04 |
References
| 1. Horne DB, Biswas K, Brown J, Bartberger MD, Clarine J, Davis CD, Gore VK, Harried S, Horner M, Kaller MR, Lehto SG, Liu Q, Ma VV, Monenschein H, Nguyen TT, Yuan CC, Youngblood BD, Zhang M, Zhong W, Allen JR, Chen JJ, Gavva NR.. (2018) Discovery of TRPM8 Antagonist ( S)-6-(((3-Fluoro-4-(trifluoromethoxy)phenyl)(3-fluoropyridin-2-yl)methyl)carbamoyl)nicotinic Acid (AMG 333), a Clinical Candidate for the Treatment of Migraine., 61 (18): [PMID:30148953] [10.1021/acs.jmedchem.8b00518] |
Source
Source(1):